Margaret Horn Sells 60,400 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 60,400 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $160.17, for a total value of $9,674,268.00. Following the sale, the chief operating officer owned 158,222 shares in the company, valued at approximately $25,342,417.74. This represents a 27.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Trading Up 3.3%

NASDAQ RVMD opened at $162.99 on Friday. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $166.50. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $145.72 and a 200-day moving average of $112.99. The company has a market cap of $34.65 billion, a PE ratio of -23.05 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the business posted ($1.13) EPS. On average, equities research analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RVMD. Royal Bank Of Canada upped their target price on shares of Revolution Medicines from $165.00 to $182.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday, April 21st. Guggenheim lifted their price target on Revolution Medicines to $205.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. HC Wainwright boosted their price target on Revolution Medicines from $169.00 to $195.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Finally, Jefferies Financial Group began coverage on Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $123.72.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Advisory Services Inc. lifted its stake in shares of Revolution Medicines by 3.0% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after buying an additional 120 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Revolution Medicines by 1.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after buying an additional 125 shares during the last quarter. Deutsche Bank AG raised its holdings in Revolution Medicines by 0.4% in the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after acquiring an additional 130 shares during the period. Signaturefd LLC raised its holdings in Revolution Medicines by 33.1% in the 4th quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after acquiring an additional 163 shares during the period. Finally, Allworth Financial LP lifted its position in Revolution Medicines by 57.2% during the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.